Brexpiprazole Dosing
For schizophrenia, start brexpiprazole at 1 mg daily, titrate to 2-4 mg daily (target 2-4 mg); for major depressive disorder as adjunctive therapy, start at 0.5-1 mg daily and titrate to a target of 2 mg daily (maximum 3 mg). 1
Standard Dosing by Indication
Schizophrenia
- Starting dose: 1 mg once daily
- Target dose: 2-4 mg once daily
- Maximum dose: 4 mg once daily
- Titration schedule: Increase to 2 mg on days 5-7, then to 4 mg on day 8 if needed 12
The FDA label provides clear guidance here, and this is supported by clinical trial data showing pooled responder rates of 46% versus 31% for placebo at the 2-4 mg dose range, yielding a number needed to treat of 7 3. In maintenance treatment, relapse prevention data strongly favor continued treatment with only 13.5% relapse versus 38.5% for placebo 2.
Major Depressive Disorder (Adjunctive)
- Starting dose: 0.5 mg or 1 mg once daily
- Target dose: 2 mg once daily
- Maximum dose: 3 mg once daily 1
The 2 mg dose appears optimal based on dose-response meta-analysis showing efficacy peaks around 2 mg (OR 1.52) with a decreasing trend at 3 mg (OR 1.40) 4. Clinical trials demonstrate a number needed to treat of 12 for response at this dose 3.
Dose Adjustments for Special Populations
Hepatic Impairment
- Moderate to severe hepatic impairment:
- MDD: Maximum 2 mg once daily
- Schizophrenia: Maximum 3 mg once daily 1
Renal Impairment
- CrCl < 60 mL/minute:
- MDD: Maximum 2 mg once daily
- Schizophrenia: Maximum 3 mg once daily 1
CYP2D6 Poor Metabolizers
- Reduce dose by 50% of the usual dose 1
- The standard label recommendation may actually overcompensate for decreased clearance in this population 5, but follow FDA guidance in clinical practice
Elderly Patients
No specific dose adjustment is mandated by the FDA label, though long-term safety data in elderly patients with MDD showed good tolerability at flexible doses of 1-3 mg daily, with 66.7% completing 26 weeks of treatment 6. Start at the lower end of the dosing range and titrate cautiously.
Obese Patients (BMI ≥35)
While not in the FDA label, pharmacokinetic modeling suggests obese patients may benefit from twice-daily dosing during the first 1-2 weeks to reach effective concentrations faster 7. However, standard once-daily dosing per label remains the official recommendation.
Drug Interactions Requiring Dose Adjustment
Strong CYP3A4 Inhibitors or CYP2D6 Inhibitors
- Reduce brexpiprazole dose by 50% 1
Strong CYP3A4 Inducers
- Double the brexpiprazole dose over 1-2 weeks 1
Combined Strong/Moderate CYP3A4 and CYP2D6 Inhibitors
- Reduce dose to 25% of usual dose 1
Administration Details
- Timing: Once daily, with or without food 1
- Formulation: Oral tablets
- Titration is mandatory - do not start at target dose due to tolerability concerns, particularly akathisia
Common Pitfalls
Akathisia risk: Occurs in 5.5% of schizophrenia patients (NNH 112) and 8.6% of MDD patients (NNH 15) 3. The gradual titration schedule helps mitigate this.
Weight gain: Approximately 10% of patients gain ≥7% body weight in short-term trials (NNH 17), with more outliers in long-term studies 23. More prominent than aripiprazole but less than olanzapine 8.
Premature discontinuation: In MDD trials, 3% discontinued due to adverse events versus 1% on placebo 3. Most common adverse event leading to withdrawal is fatigue.
Forgetting dose adjustments: Always check for hepatic/renal impairment, CYP2D6 metabolizer status, and concomitant medications before prescribing.